Endogenex, a clinical-stage medical technology company pioneering a new treatment for type 2 diabetes (T2D), announced the closing of a $50 million extension of its Series C financing. Arboretum Ventures joined as a new lead investor, with existing investors participating as well. The proceeds from this financing will fund completion of the company's pivotal ReCET Clinical Study and support the company's regulatory path to FDA approval.

This extension builds on the $88 million Series C that Endogenex closed in June 2024, bringing total Series C financing to $138 million.